Insider transactions

K Peony Yu

CIK 1621328 · Chief Medical Officer · last filed 2023-06-16

K Peony Yu is a Chief Medical Officer who has filed 80 SEC Form 4 insider transactions across 2 companies since 2014. The most recent filing, for STAA, was dated Jun 16, 2023. Across all open-market trades the lifetime net is −$13.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $64.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$64.7K
Companies
2
Total Filings
80
Lifetime Open-Market Net
-$13.40M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

FGEN price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O FIBROGEN, INC.
409 ILLINOIS ST.,
SAN FRANCISCO, CA 94158
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
STAA Director 2,786 $23.23 $64.7K $0 4 2023-06-16
KYNTRA BIO, INC. (FGEN) Delisted Chief Medical Officer 7,692 $9.75 $75.0K -$13.40M 76 2020-12-17

Recent Filings

80 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-06-16 STAA Exer (M) +1,709 $0 EDGAR
2022-06-17 STAA Exer (M) +355 $0 EDGAR
2021-06-25 STAA Mixed +404 $0 EDGAR
2021-01-26 STAA Grant (A) +318 $0 EDGAR
2020-12-17 KYNTRA BIO, INC. (FGEN) Delisted Sell (S) −3,350 -$139.4K EDGAR
2020-12-09 KYNTRA BIO, INC. (FGEN) Delisted Tax (F) −3,292 -$138.2K EDGAR
2020-09-18 KYNTRA BIO, INC. (FGEN) Delisted Sell (S) −3,351 -$147.5K EDGAR
2020-09-10 KYNTRA BIO, INC. (FGEN) Delisted Tax (F) −3,291 -$138.7K EDGAR
2020-09-04 KYNTRA BIO, INC. (FGEN) Delisted Mixed — -$328.9K EDGAR
2020-07-28 KYNTRA BIO, INC. (FGEN) Delisted Sell (S) −3,351 -$141.9K EDGAR
Showing 1–10 of 80
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.